Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPA Trial
2024-520093-34-00Phase 3Authorised
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jan 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of triptorelin and bicalutamide in acinar prostate cancer (APC) (2 arms), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Biochemical disease-free survival (bDFS). Planned start Jan 2025; status: authorised.
02
Drugs
triptorelinbicalutamide
03
Conditions
acinar prostate cancer (APC)
Beyond the preview
Go deeper on 2024-520093-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520093-34-00.